Opioid agonist treatment in the time of fentanyl: What can we learn from emerging evidence?

Shalini Arunogiri^{1

2}, Suzanne Nielsen^{1

2}

Affiliations

¹ Turning Point, Eastern Health, Melbourne, Australia.
² Monash Addiction Research Centre and Eastern Health Clinical School, Monash University, Melbourne, Australia.

Shalini Arunogiri et al. Drug Alcohol Rev. 2020 Mar.

. 2020 Mar;39(3):203-204.

doi: 10.1111/dar.13029. Epub 2020 Jan 9.

Shalini Arunogiri^{1

2}, Suzanne Nielsen^{1

2}

¹ Turning Point, Eastern Health, Melbourne, Australia.
² Monash Addiction Research Centre and Eastern Health Clinical School, Monash University, Melbourne, Australia.

No abstract available

References

1. Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy 2019;71:183-8.
1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths-United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2019;67:1419-27.
1. Lisa B, Jessica H. Evidence synthesis-the opioid crisis in Canada: a national perspective. Health Promot Chronis Dis Prev Can 2018;38:224-33.
1. Ochalek TA, Parker MA, Higgins ST, Sigmon SC. Fentanyl exposure among patients seeking opioid treatment. J Subst Abus Treat 2019;96:23-5.
1. Sordo L, Barrio G, Bravo MJ et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550.